It fascinates me to see this company, with a proven comprehensive record of complete failure, keep pulling the same tricks… and some people keep lapping it up. I’d urge anyone to look through previous annual results, take a look at what was predicted every year by the ceo and what was actually delivered every year. It’s totally bonkers - especially the bit about the biological pathogen detectors in during covid. |
Cry Baby cyberdyne1,
"Don’t write it off quite so quickly. I’m sure in a week or two we will be in the 8’s."
Let's diarise 4:30pm on Wed 5th March to review. In between now and then you can take some time to think about why Kromek deserves to trade on a forward PE ratio of 50 times - which is what it would be on at an 8p share price!
JakNife |
Don’t write it off quite so quickly. I’m sure in a week or two we will be in the 8’s. |
Now that the rampers together with their sizeable short-term gains (I take my hat off to their skills) appear to have moved on to new vistas, normal service will likely be resumed on Kromek.
The Siemens money will likely be spent rapidly on supporting the ongoing egregious cash-burn and servicing/repaying debt.
Selling the family silver is normally the last resort.
ALL IMO. DYOR. QP |
Thanks for clarifying what it does tell me is I need to do some further research into this vertical. Although I appreciate as you say this is a premium segment with the NHS having only (so far) invested in 5 of them, the growing purchasing power of the private sector should also be considered. Plus the application of AI scan analysis which needs very high resolution scanning technology to be effective. All this means Kromek have a guaranteed growing market, with their tech now being truly commercialised. |
PCCT is new and developing but still nascent - all CT manufacturers as I listed above will be exploring/developing their own tech. Any that use CZT or CdTe as their semiconductor of choice are likely to get it from KMK |
Philips, GEHC, Siemens , Samsung and Canon are all exploring or producing CT scanners called photon counting CT or PCCT scannersCanon, Philips, and a small animal scanner company called MARS all use CZT, GEHC use Silicon.Siemens and Samsung use Cadmium Telluride or CdTe for short (not CzT) |
So Croasdale what you are saying is the 7-year colab is for a CZT gamma/photo counting premium application. As a relatively recent investor your knowledge on this is a lot deeper than mine. But there is a definite another player out there. Could this be Philips or Samsung even? Reading the RNS may give some clues, but it does indicate a major player, but maybe not an existing big name in the business? |
CZT gamma cameras are at the very premium end of the market and very expensive and hence don't sell in large numbers compared to their cheaper analogue cousins. To illustrate my point SD have sold 5 scanners only in nearly 5 years in the UK. The first was installed in Bath in Nov 2020 after Dept refurb. The latest will go into Newcastle in March/April 2025 |
What is not clear is how much of the $25m or indeed $37m is prepayment for CZT tiles for Siemens to use in their evaluation/beta testing scanners likely to be produced in 2025/2026 . Is it $5m or $10m or more .In other words KMK have money in the bank for goods yet produced and investors have no idea how many CZT tiles they need to make in 2025-2028 to satisfy the contract.It's likely Siemens will announce their new scanner (evaluation only) in one of the big congresses in US or Europe , ie June, Oct or Nov. Full roll out of production model will be 2026 for sure |
That was likely for photon counting CT - not SPECT applications. note the Siemens deal is just for SPECT applicationsThere are 3 gamma camera SPECT companies - GE, Siemens and Spectrum Dynamics - there is another very small company called Mediso in Hungary with a few percent market share . gE produce their own CZT, Siemens and SD are getting it from Kromek. There is no other Tier 1 company deal to come in SPECT |
There is also the Nov 2023 collaboration agreement with a new Tier 1 partner. Even if one of these was Siemens (we don’t know) we still have another major one in the mix seemingly about to bear fruit. The Siemens agreement is non exclusive, so not a sell out. |
It's potentially a high value situation as the technology being developed is the latest as opposed to the older tech in the Siemens deal. |
Well we know there is at least one other tier one from April 2023 rns and that contract could eventually eclipse the Siemens one in value.Kromek Group plc (AIM: KMK) , a leading developer of radiation and bio-detection technology solutions for the advanced imaging and CBRN detection segments, is pleased to announce that it has entered into an initial seven-year agreement with a Tier 1 OEM ("the Customer") to develop CZT-based detectors for use in the Customer's advanced medical imaging scanners. The Customer is a leading health-technology company with market-leadership positions in multiple businesses. |
What other Tier 1s - other Tier 1s already have contracts or produce their own CZT - name one?Siemens want the tech to buy into the CZT market - 15 years later than GE healthcare! KMK needed cash so they front loaded the contract . Quid pro quo.The lack of market reaction says it all. The wolf at the door has been satiated- for a year or two |
Receiving the expected funds so promptly and well before the end March deadline shows how committed Siemens is with the contract. They want to move things on at pace in a highly competitive market. As the contract says Siemens will most likely make other additional purchases as roll out gathers pace. I’m sure other Tier 1’s are currently in Kromek contract talks and this will expedite these. In the scanner market having the latest product is paramount. |
You buyin jackknife? |
Wow correction to my post. $25m RECEIVED on 17/2/25! |
A much needed perspective on the Siemens deal compared with all the deals announced last year:
Kromek receives $1.6m in advanced imaging orders Kromek receives £1.4m CBRN order for EU stockpile Kromek granted £1.3m under Horizon Europe scheme Kromek receives $2.1m security screening order Kromek receives new Nuclear Security contract Kromek selected for UK Government Framework Kromek awarded £2.0m contract from UK MOD Kromek selected for UK Government Framework Kromek receives $25m of a $37m contract by 27/3/25
So about a factor of x5 the t/o in just one deal |
You'll see your shorts I'll see my longs. Caserasera |
 Karimgrant,
"Wait for the next contract to be announced, things are moving fast."
Look back through the 2024 RNSs and you will find pearls such as:
Kromek receives $1.6m in advanced imaging orders Kromek receives £1.4m CBRN order for EU stockpile Kromek granted £1.3m under Horizon Europe scheme Kromek receives $2.1m security screening order Kromek receives new Nuclear Security contract Kromek selected for UK Government Framework Kromek awarded £2.0m contract from UK MOD Kromek selected for UK Government Framework
All these new contract RNSs and yet, when you read the interim results:
H1 revenue, for the six months to the end of October, was just £3,676k, which was *DOWN* 48.2% compared to H1 from 2023!
That's because Kromek's management are hopelessly dishonest!
1. They put out RNSs with huge headline numbers in them that never actually turn up in the revenue line, and
2. Whilst they happily announce all the new contracts they never tell you about the contract losses or that some contracts are just repeat orders from existing clients.
The basic first test of whether or not to invest in a company is always an assessment of whether management are hard-working honest folk or crooks on the make and the take. Kromek fails the basic first test!
JakNife |
Wait for the next contract to be announced, things are moving fast. |
Mm's pulling it down before the next good news leg up. Crafty or what. |
Shareprofits crew about to get liquidated City knows another tr1 before news next week.Keep your eyes open, squeeze soon |
CEO very upbeat on prospects for the company:
Watch as Arnab reflects on the role of NETPark in Kromek’s development and shares what’s next for the company as it looks to expand its impact across these vital industries. |